Coldstream Capital Management Inc. Raises Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Coldstream Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,432 shares of the medical research company’s stock after acquiring an additional 681 shares during the period. Coldstream Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $3,945,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. WealthPlan Investment Management LLC raised its holdings in Thermo Fisher Scientific by 239.4% in the third quarter. WealthPlan Investment Management LLC now owns 3,394 shares of the medical research company’s stock worth $1,718,000 after buying an additional 2,394 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in Thermo Fisher Scientific by 20.3% in the third quarter. Venturi Wealth Management LLC now owns 1,065 shares of the medical research company’s stock worth $539,000 after buying an additional 180 shares during the last quarter. Girard Partners LTD. raised its holdings in Thermo Fisher Scientific by 4.0% in the third quarter. Girard Partners LTD. now owns 29,850 shares of the medical research company’s stock worth $15,110,000 after buying an additional 1,146 shares during the last quarter. Dai ichi Life Insurance Company Ltd raised its holdings in Thermo Fisher Scientific by 35.3% in the third quarter. Dai ichi Life Insurance Company Ltd now owns 32,547 shares of the medical research company’s stock worth $16,474,000 after buying an additional 8,497 shares during the last quarter. Finally, Pictet North America Advisors SA grew its position in Thermo Fisher Scientific by 35.7% during the third quarter. Pictet North America Advisors SA now owns 16,590 shares of the medical research company’s stock valued at $8,397,000 after buying an additional 4,362 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.3 %

Shares of TMO traded down $1.90 during mid-day trading on Monday, hitting $593.40. 268,849 shares of the company’s stock were exchanged, compared to its average volume of 1,515,260. The company has a market cap of $226.51 billion, a price-to-earnings ratio of 38.18, a P/E/G ratio of 2.47 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock’s 50-day moving average is $576.74 and its 200-day moving average is $543.41.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold a total of 32,000 shares of company stock valued at $18,486,980 over the last quarter. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Barclays upped their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. The Goldman Sachs Group raised their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James increased their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Finally, Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.